High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• High-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS) is rare, with an evolving definition and diagnostic challenges.
• Understanding the molecular characteristics of HGBCL-NOS is crucial for accurate diagnosis and treatment.

Purpose of the Study:

• To molecularly characterize HGBCL-NOS and compare it with diffuse large B-cell lymphoma (DLBCL-NOS) and Burkitt lymphoma (BL).
• To assess the utility of existing molecular classifiers in HGBCL-NOS.

Main Methods:

• Analysis of 92 HGBCL-NOS tumors using molecular profiling techniques.
• Comparison with DLBCL-NOS and BL cohorts.
• Application of LymphGen classifier and a DLBCL-NOS vs. BL classifier.
• Centralized pathology review.

Main Results:

• HGBCL-NOS exhibits a heterogeneous molecular landscape, with features of both DLBCL-NOS and BL, including enrichment of BL-associated genes (MYC-rearrangement, dark zone signature).
• LymphGen classifier assigned subtypes to 34% of HGBCL-NOS, with 31% of activated B-cell-like (ABC) cases classified as MCD.
• Pathology review reclassified nearly half of cases as DLBCL-NOS without identifying a more homogenous HGBCL-NOS subgroup.

Conclusions:

• Molecular testing can assign a subset of HGBCL-NOS to established categories.
• Due to its rarity and diagnostic complexity, HGBCL-NOS should be considered for inclusion in biomarker-driven DLBCL clinical trials.